188 related articles for article (PubMed ID: 36864492)
1. DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t(8;21) acute myeloid leukemia.
He S; Li Y; Shi X; Wang L; Cai D; Zhou J; Yu L
Clin Epigenetics; 2023 Mar; 15(1):37. PubMed ID: 36864492
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation landscape reveals GNAS as a decitabine-responsive marker in patients with acute myeloid leukemia.
He S; Li Y; Wang L; Li Y; Xu L; Cai D; Zhou J; Yu L
Neoplasia; 2024 Mar; 49():100965. PubMed ID: 38245923
[TBL] [Abstract][Full Text] [Related]
3. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors.
Negrotto S; Ng KP; Jankowska AM; Bodo J; Gopalan B; Guinta K; Mulloy JC; Hsi E; Maciejewski J; Saunthararajah Y
Leukemia; 2012 Feb; 26(2):244-54. PubMed ID: 21836612
[TBL] [Abstract][Full Text] [Related]
4. The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine.
Li Y; Mao X; Li M; Li L; Tong X; Huang L
Clin Epigenetics; 2024 Jan; 16(1):16. PubMed ID: 38254153
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of newly diagnosed acute myeloid leukemia with myelodysplasia related changes and elderly acute myeloid leukemia following decitabine therapy in combination with priming regimen.
Lai B; Mu Q; Zhang Y; Chen Y; Yan X; Ouyang G
Hematology; 2021 Dec; 26(1):751-757. PubMed ID: 34555298
[TBL] [Abstract][Full Text] [Related]
6. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
Wang L; Luo J; Chen G; Fang M; Wei X; Li Y; Liu Z; Zhang Y; Gao S; Shen J; Wang X; Gao X; Zhou W; Ma Y; Liu H; Li X; Yang L; Sun K; Yu L
Clin Epigenetics; 2020 Sep; 12(1):132. PubMed ID: 32873343
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
[TBL] [Abstract][Full Text] [Related]
8. The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML).
Yan-Fang T; Jian N; Jun L; Na W; Pei-Fang X; Wen-Li Z; Dong W; Li P; Jian W; Xing F; Jian P
BMC Med Genet; 2013 Jul; 14():74. PubMed ID: 23870168
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
Yan P; Frankhouser D; Murphy M; Tam HH; Rodriguez B; Curfman J; Trimarchi M; Geyer S; Wu YZ; Whitman SP; Metzeler K; Walker A; Klisovic R; Jacob S; Grever MR; Byrd JC; Bloomfield CD; Garzon R; Blum W; Caligiuri MA; Bundschuh R; Marcucci G
Blood; 2012 Sep; 120(12):2466-74. PubMed ID: 22786882
[TBL] [Abstract][Full Text] [Related]
10. Impact of Global and Gene-Specific DNA Methylation in de Novo or Relapsed Acute Myeloid Leukemia Patients Treated with Decitabine.
Zhang LY; Yuan YQ; Zhou DM; Wang ZY; Ju SG; Sun Y; Li J; Fu JX
Asian Pac J Cancer Prev; 2016; 17(1):431-7. PubMed ID: 26838251
[TBL] [Abstract][Full Text] [Related]
11. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia.
Zhou S; Liu P; Zhang H
Mol Med Rep; 2017 Jul; 16(1):281-287. PubMed ID: 28498449
[TBL] [Abstract][Full Text] [Related]
13. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
14. Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.
Ma YY; Zhao M; Liu Y; Zhao DF; Wang LX; Chen XP; Li L
Hematology; 2019 Dec; 24(1):507-515. PubMed ID: 31242832
[No Abstract] [Full Text] [Related]
15. Decitabine Enhances Acute Myeloid Leukemia Cell Apoptosis through SH3BGRL Upregulation.
Chen X; Liu F; Rong D; Xu L; Tong X; Wang H
Anticancer Agents Med Chem; 2022; 22(12):2274-2281. PubMed ID: 34963436
[TBL] [Abstract][Full Text] [Related]
16. TBC1D16 predicts chemosensitivity and prognosis in adult acute myeloid leukemia (AML) patients.
Liu H; Chen P; Yang YL; Zhu KW; Wang T; Tang L; Liu YL; Cao S; Zhou G; Zeng H; Zhao XL; Zhang W; Chen XP
Eur J Pharmacol; 2021 Mar; 895():173894. PubMed ID: 33476656
[TBL] [Abstract][Full Text] [Related]
17. Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy.
Ni J; Hong J; Long Z; Li Q; Xia R; Zeng Q
Int J Lab Hematol; 2020 Dec; 42(6):849-857. PubMed ID: 32730663
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Gore L; Triche TJ; Farrar JE; Wai D; Legendre C; Gooden GC; Liang WS; Carpten J; Lee D; Alvaro F; Macy ME; Arndt C; Barnette P; Cooper T; Martin L; Narendran A; Pollard J; Meshinchi S; Boklan J; Arceci RJ; Salhia B
Clin Epigenetics; 2017; 9():108. PubMed ID: 29034009
[TBL] [Abstract][Full Text] [Related]
19. Methylation-associated silencing of BASP1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
Zhou L; Fu L; Lv N; Liu J; Li Y; Chen X; Xu Q; Chen G; Pang B; Wang L; Li Y; Zhang X; Yu L
Exp Mol Med; 2018 Apr; 50(4):1-8. PubMed ID: 29674693
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
Xu Q; Li Y; Jing Y; Lv N; Wang L; Li Y; Yu L
Int J Cancer; 2020 Mar; 146(5):1457-1467. PubMed ID: 31344264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
